Good Diet To Control Cholesterol

Good Diet To Control Cholesterol 5 out of 5 based on 91 ratings.
 

FDA to review Vytorin cholesterol drug study The Food and Drug Administration said it was not advising doctors to stop prescribing Vytorin but the agency’s announcement unnerved investors and sent shares of the two companies lower. The FDA said it could take Good Diet To Control Cholesterol up to six months to review final results of the study called Enhance and decide if any regulatory action was needed. A final report from the companies could be available within a couple months FDA officials said.

High LDL is commonly believed to be a major risk factor for heart disease. Good Diet To Control Cholesterol drugs that cut LDL are among the largest selling drugs in the world and also include Pfizer Inc’s Lipitor and Astra Zeneca Plc’s Crestor. Shares of Pfizer and Astra Zeneca were also lower after the FDA announcement.

The agency’s review put an even bigger spotlight on a debate over Vytorin’s value in the wake of the Enhance results early last week and concern over a long delay in releasing the data. Major medical groups prominent cardiologists and U. S.

The Enhance study examined Vytorin against Zocor alone in patients with a rare genetic predisposition to dangerously high cholesterol levels. Vytorin failed to halt the clogging of neck arteries better than Zocor alone but it did a better job of reducing LDL cholesterol. Beyond Vytorin the FDA said it also would review “whether any changes to FDA’s current approach to drugs that lower LDL cholesterol are warranted.” High LDL is commonly believed to be a major risk factor for heart disease. Drugs that cut LDL are among the largest selling drugs in the world and also include Pfizer Inc’s Lipitor and Astra Zeneca Plc’s Crestor. Shares of Pfizer and Astra Zeneca were also lower after the FDA announcement.

NYSE. The two stocks have fallen more than 20 percent since the results of the study were released. Merck and Schering-Plough sell Vytorin and Zetia in a joint venture and the products have combined annual sales of about $5 billion.

S. lawmakers have weighed in while prescriptions for the drug have slipped. Merck & Co Inc’s shares closed down 3.6 percent at $47.79 on the New York Stock Exchange. They had earlier fallen as much as 14 percent.

NYSE. The two stocks have fallen more than 20 percent since the results of the study were released. Merck and Schering-Plough sell Vytorin and Zetia in a joint venture and the products have combined annual sales of about $5 billion.

High LDL is commonly believed to be a major risk factor for heart disease. Drugs that cut LDL are among the largest selling drugs in the world and also include Pfizer Inc’s Lipitor and Astra Zeneca Plc’s Crestor. Shares of Pfizer and Astra Zeneca were also lower after the FDA announcement. Lipitor Zocor and other drugs in the same statin class have consistently shown the ability to reduce heart attacks and strokes by up to 30 percent. Merck and Schering-Plough have been criticized by doctors industry analysts and lawmakers for delaying presentation of results from the trial which was concluded in 2006. Deborah Cohn a professor of marketing at Touro College Graduate School of Business in New York said the delay in releasing the results had caused an understandable backlash.

Lipitor Zocor and other drugs in the same statin class have consistently shown the ability to reduce heart attacks and strokes by up to 30 percent. Merck and Schering-Plough have ben criticized by doctors industry analysts and lawmakers for delaying presentation of results from the trial which was concluded in 2006. Deborah Cohn a professor of marketing at Touro College Graduate School of Business in New York said the delay in releasing the results had caused an understandable backlash. Spokesmen for Merck and Schering-Plough both welcomed the FDA’s statement. Merck spokesman Christopher Garland said the FDA announcement “appropriately communicates information about the Enhance trial as well as information about Vytorin and Zetia.

In the meantime patients with questions about the Enhance study should talk with their doctors the FDA advised. Simvastatin

Good Diet To Control Cholesterol

is the generic name for Zocor. Vytorin combines Zocor with a newer cholesterol-fighting pill called Zetia.

S. lawmakers have weighed in while prescriptions for the drug have slipped. Merck & Co Inc’s shares closed down 3.6 percent at $47.79 on the New Good Diet To Control Cholesterol York Stock Exchange. They had earlier fallen as much as 14 percent.

The agency’s review put an even bigger spotlight on a debate over Vytorin’s value in the wake of the Enhance results early last week and concern over a long delay in releasing the data. Major medical groups prominent cardiologists and U. S. lawmakers have weighed in while prescriptions for the drug have slipped. Merck & Co Inc’s shares closed down 3.6 percent at $47.79 on the New York Stock Exchange. They had earlier fallen as much as 14 percent.

Lipitor Zocor and other drugs in the same statin class have consistently shown the ability to reduce heart attacks and strokes by up to 30 percent. Merck and Schering-Plough have been criticized by doctors industry analysts and lawmakers for delaying presentation of results from the trial which was concluded in 2006. Deborah Cohn a professor of marketing at Touro College Graduate School of Business in New York said the delay in releasing the results had caused an understandable backlash –

  1. Beyond Vytorin the FDA said it also would review “whether any changes to FDA’s current approach to drugs that lower LDL cholesterol are warranted
  2. FDA to review Vytorin cholesterol drug study The Food and Drug Administration said it was not advising doctors to stop prescribing Vytorin but the agency’s announcement unnerved investors and sent shares of the two companies lower
  3. In the meantime patients with questions about the Enhance study should talk with their doctors the FDA advised
  4. A final report from the companies could be available within a couple months FDA officials said
  5. Shares of Schering-Plough Corp which had dropped as much as 13 percent closed down 5

. Spokesmen for Merck and Schering-Plough both welcomed the FDA’s statement. Merck spokesman Christopher Garland said the FDA Good Diet To Control Cholesterol announcement “appropriately communicates information about the Enhance trial as well as information about Vytorin and Zetia.

FDA to review Vytorin cholesterol drug study The Food and Drug Administration said it was not advising doctors to stop prescribing Vytorin but the agency’s announcement unnerved investors and sent shares of the two companies lower. The FDA said it could take up to six months to review final results of the study called Enhance and decide if any regulatory action was needed. A final report from the companies could be available within a couple months FDA officials said.

Tags: , , <BR/>

Leave a Reply

You must be logged in to post a comment.